Airsculpt Technologies Inc (AIRS)vsNovartis AG ADR (NVS)
AIRS
Airsculpt Technologies Inc
$2.13
-10.50%
HEALTHCARE · Cap: $173.03M
NVS
Novartis AG ADR
$138.99
-0.27%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 37514% more annual revenue ($56.69B vs $150.72M). NVS leads profitability with a 22.5% profit margin vs -7.8%. NVS earns a higher WallStSmart Score of 51/100 (C-).
AIRS
Hold38
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+34.4%
Fair Value
$3.23
Current Price
$2.13
$1.10 discount
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$138.99
$45.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 200.0% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -11.2% — below average capital efficiency
Revenue declined 2.5%
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AIRS
The strongest argument for AIRS centers on Price/Book, EPS Growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : AIRS
The primary concerns for AIRS are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
AIRS profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
AIRS carries more volatility with a beta of 2.29 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 38/100), backed by strong 22.5% margins. AIRS offers better value entry with a 34.4% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Airsculpt Technologies Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Airsculpt Technologies Inc (AIRS) is at the forefront of the aesthetic medical technology sector, specializing in its proprietary AirSculpt® procedure, which sets a new standard for minimally invasive body contouring while prioritizing patient safety and comfort. The company is aggressively expanding its network of licensed practitioners and utilizing innovative technologies to solidify its competitive advantage in the rapidly growing non-invasive cosmetic treatment market. With rising global demand for aesthetic solutions, Airsculpt is well-positioned to capture market share and broaden its service offerings, driving robust growth and long-term value for its investors.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?